Is the Healthcare Facility Level Sufficient for Assessing the Impact of 2-Step Clostridioides difficile Testing?
- PMID: 37279961
- DOI: 10.1093/cid/ciad332
Is the Healthcare Facility Level Sufficient for Assessing the Impact of 2-Step Clostridioides difficile Testing?
Keywords: Clostridioides difficile; facility level reporting; hospital onset.
Conflict of interest statement
Potential conflicts of interest. D. N. G. is a consultant for Sebela and Destiny Pharma and holds technology for the prevention of CDI licensed to Destiny Pharma. D. N. G. also reports an issued and expired patent for methods and composition for prevention and treatment of C. difficile–associated disease. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level.Clin Infect Dis. 2023 Oct 5;77(7):1043-1049. doi: 10.1093/cid/ciad334. Clin Infect Dis. 2023. PMID: 37279965 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources